Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Item

http://www.wikidata.org/entity/Q28256478

Q28256478

about

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor Unveiling changes in the landscape of patient populations in cancer early drug development Developmental therapeutics for inflammatory breast cancer: Biology and translational directions Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Lapatinib in the treatment of breast cancer Phosphotyrosine signaling proteins that drive oncogenesis tend to be highly interconnected Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors Lapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffolds Integrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell Lines ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.Unnatural polyketide analogues selectively target the HER signaling pathway in human breast cancer cells.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer.Development of the rat model of lapatinib-induced diarrhoea.Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer Metabolism considerations for kinase inhibitors in cancer treatment Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

P2860

Q24653999-BCCE9ABE-E47A-4557-BB57-B3ABFFBFA630 Q26823978-3E7B33FB-09D4-4C3B-B0BF-86ADA69A1E70 Q26824799-58361296-FE9E-415B-8075-60C5FE529FD4 Q27025863-64C7CEDD-279C-4876-9FDE-ED50D1373D49 Q27342948-B87CB0A9-099F-45EC-A37E-8A62A9C08BBB Q28073826-78037426-147A-4026-B7B7-7E762669FE76 Q28075322-F1FB5E5B-E28E-4E26-8BF0-9E471868EA0B Q28081844-AB528B14-ED2A-4130-B4A4-22D1651849D7 Q28250382-EA9360F2-0CEE-4414-A413-3C6A52998A61 Q28284451-17A82C69-D882-4EC7-B3FE-D634E31AE833 Q28292264-1886C094-B599-4ACE-99B5-6DCA1417EC08 Q28486270-7D0396AB-F782-471C-AB84-2626755DE79D Q28553930-A4E6A1EA-322F-4233-BBD7-093FE87CEAD2 Q30457869-FF6A137A-006C-4E61-A1BC-F0D9348B71C0 Q30500245-58ED2B41-65ED-4FB2-902E-B9D7B3BEE1B2 Q30758991-9C5B5944-F164-4EE9-B845-88D3D1935420 Q33396953-30C550DE-1730-405D-A18B-9388F2725180 Q33428194-1E78CB38-6BB7-4082-AA63-3B889301BF72 Q33556988-69CEE027-0038-4C01-8839-85D824FD5756 Q33648150-28AB6ED0-B388-478D-82F1-1B6579F3BCD2 Q33816185-9B761DE3-7035-4417-91BB-6501FE3466B3 Q33829639-D345A5E0-6FB4-482D-9364-17CC40B43ADE Q33999288-6DF76D2C-4708-4484-95B6-F5E3CDADD413 Q34095748-E628D877-23D6-4A96-8EC4-244FE8801CA8 Q34134390-BCF83871-5908-4890-96B4-E7EF0565FAB0 Q34140167-2256F105-60A5-44CF-B305-B57664F8A523 Q34193975-6307BBDB-BFD1-4A63-A4DF-17F8DF2B0147 Q34214918-78A56101-E006-443F-9B48-F2C041DF258F Q34268618-9CFD706C-FBD7-48CC-833C-B7DAE3E63C34 Q34363419-4D6B8D02-E5AE-4917-9753-22C83849DB34 Q34417423-BCD3AD66-1761-4A43-9580-A89F8B3D9109 Q34417920-1EA81CD6-191E-459B-81DB-CBA49AF40A88 Q34504365-34529BAC-0035-4D21-864E-57439DC28562 Q34530485-8F810F01-46B9-4506-9665-A148FE568B9E Q34551761-FC469C2D-3854-4AF5-AA95-ADE7737F119F Q34611634-8BF9547F-D4DF-4785-AADA-824ADE3EB9E2 Q34611637-87F7E5E8-DACA-42EE-AF6A-6595EAED8A82 Q34613543-5D578975-D362-48B3-8B64-F18D1120F3D4 Q34632169-C47F8158-84C9-4FEC-A02A-6013CC16E648 Q34650878-C0D6A2A0-C8FC-4160-AED1-1E7BD8F5A22A

P2860

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Item

http://www.wikidata.org/entity/Q28256478

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu